# Veru

Source: https://onco.cc/companies/veru/  
OnCo record `veru` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Veru is a Miami company whose oncology programmes were the selective androgen receptor modulator enobosarm for AR-positive, ER-positive breast cancer and the microtubule disruptor sabizabulin for prostate cancer, which was halted in 2022.

## Summary

Veru Inc., listed on Nasdaq, moved from sexual health products into oncology and metabolic disease. Sabizabulin, an oral microtubule disruptor, was tested in metastatic castration-resistant prostate cancer (VERACITY) until the trial was stopped in 2022 and then, controversially, in COVID-19. Enobosarm, a selective androgen receptor modulator, was studied in androgen receptor-positive, oestrogen receptor-positive metastatic breast cancer (ARTEST, ENABLAR-2) before the company redirected it to preserving muscle during weight-loss therapy. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Veru Inc.; Veru Pharma
- Tags: ctgov-sponsor
- HQ: Miami, FL
- Type: biotech
- Website: https://verupharma.com

## Sources

- Official website: https://verupharma.com
- ClinicalTrials.gov: trials led by Veru: https://clinicaltrials.gov/search?lead=Veru
- Wikipedia: https://en.wikipedia.org/wiki/Veru_Inc.

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Hormonal Therapy](https://onco.cc/fronts/hormonal/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)

---
JSON: https://onco.cc/api/v1/entities/veru.json